Yeda Research and Development — Weizmann Institute's Technology-Transfer Company (Rehovot)

What it is — Yeda Research and Development Company Ltd. is a wholly owned subsidiary of the Weizmann Institute of Science, founded in 1959 specifically to hold and commercialise the intellectual property generated by the Institute's researchers.

What it does — Yeda files and manages patents on Institute inventions, negotiates licensing and royalty agreements with pharmaceutical and technology companies, and returns roughly 40% of royalty income to the inventing scientists, reinvesting the remainder into the Institute's research budget.

Results — the model's biggest success is glatiramer acetate, licensed to Teva Pharmaceutical Industries in the 1980s and marketed as Copaxone for multiple sclerosis; combined with Rebif (multiple sclerosis, with Merck Serono), an NDS satellite-encryption system, and later Erbitux (cancer, with ImClone/Sanofi), these inventions have driven the bulk of Yeda's royalties. By 2013 the Institute was earning an estimated $50–100 million a year in pharmaceutical royalties, and by 2022 products originating from Institute research were generating more than $23 billion in global sales; recent reporting puts cumulative royalty income over a six-year period above $2 billion (over NIS 1 billion), consistently placing Weizmann among the top five academic institutions worldwide for royalty income. Beyond licensing, roughly 120 startup companies have been founded on Weizmann research through 2024, supported since 2021 by a dedicated pre-commercialisation research unit, BINA.

Why it matters — Yeda shows an extreme but instructive case of the "university-owned IP holding company" model: a single, decades-long licensing relationship (Copaxone) funded a large share of one research institute's non-grant income, and demonstrates how concentrated basic-research strength in a narrow field (immunology/neuroscience) can be converted into durable commercial return, provided the institute retains full IP ownership and shares royalties generously with inventors.

Caveat — the great majority of Yeda's income has historically come from a small handful of blockbuster drugs rather than a broad, evenly distributed patent portfolio, and Copaxone revenue has declined substantially since going off-patent in the mid-2010s — a reminder that concentrated technology-transfer windfalls are not easily repeated or guaranteed to recur.

Read the full analysis: https://www.yedarnd.com/

Read the full analysis: https://www.yedarnd.com/